Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
L-Phenylephrine in α1A Cardiovascular Research
2026-08-17
L-Phenylephrine provides a defined adrenergic α1A receptor agonist system for connecting vasoconstriction, baroreflex physiology, cardiomyocyte stress responses, and gene-expression assays. This workflow translates sex-specific hypertension findings into practical in vitro and in vivo experimental designs with explicit controls and troubleshooting steps.
-
GDC-0994: Reading ERK1/2 Signaling in Context
2026-08-17
GDC-0994 is a selective ERK1/2 inhibitor for separating pathway activation from downstream biological effects. This guide translates cancer and zebrafish cholestasis findings into practical assay and interpretation strategies.
-
6-Thioguanine and EV71: BIRC3-Linked Autophagy
2026-08-16
The reference study identifies 6-thioguanine as an in vitro inhibitor of Enterovirus 71 replication and links this activity to reduced BIRC3 expression and suppression of complete autophagy. Its concentration-response and mechanistic findings provide a useful framework for evaluating repurposed antineoplastic agents in antiviral research, while remaining limited to cell-based evidence.
-
Capsazepine Workflows for TRPV1 Research
2026-08-15
Capsazepine provides a controllable pharmacological route to test TRPV1-dependent calcium signaling, nociception inhibition, and sensory-neuron responses. This guide translates a recent cannabidiol pain study into practical antagonist-control experiments while also addressing TRPM8 channel inhibition, formulation, selectivity, and apoptosis research.
-
KPT-330 and the Translational Logic of CRM1 Inhibition
2026-08-14
CRM1 inhibition offers a mechanistically grounded strategy for restoring nuclear control over tumor suppressors and stress responses. This thought-leadership perspective examines how KPT-330 (Selinexor) can support biomarker-led cancer research, combination design, and more disciplined translation from models to therapeutic hypotheses.
-
Thermosensitive ROS-Scavenging Hydrogel for Diabetic Wounds
2026-08-14
The reference study introduces TGF-β1@MATH, an adhesive thermosensitive hydrogel that combines ROS-scavenging MnO2 nanozymes with controlled TGF-β1 delivery and temperature-dependent stiffening. In diabetic mice, this integrated design improved re-epithelialization, collagen deposition, angiogenesis, and regulatory T-cell recruitment, providing a mechanistically coordinated approach to chronic wound repair.
-
Hoechst 33342 for Senescence Assay Design
2026-08-13
Learn how Hoechst 33342 nuclear stain can strengthen live and fixed-cell senescence workflows without being mistaken for a senescence marker. This guide connects nuclear quality control, mitochondrial readouts, and the 2025 dermal fibroblast study by Zhou et al. to practical assay decisions.
-
Live-Dead Cell Staining Kit: Practical Guide
2026-08-13
Learn how Calcein-AM and Propidium Iodide dual staining supports reproducible cell viability assays in microscopy, flow cytometry, cytotoxicity studies, and biomaterial screening. This workflow-focused guide also explains how to interpret viability data in the context of the 2025 GelMA/QCS/Ca2+ hemostatic adhesive study.
-
CSRP2–PDGFRA Signaling in Glioma
2026-08-12
A 2026 study identifies CSRP2 as a mesenchymal glioma-associated regulator that connects PRC1-linked promoter remodeling with PDGFRA/PI3K/AKT signaling. Its integrated genomic, epigenomic, cellular, and xenograft analyses provide a mechanistic framework for interpreting CSRP2 as a biomarker candidate, while therapeutic relevance remains unresolved.
-
Merimepodib (VX-497): IMPDH Assay Logic
2026-08-12
Merimepodib (VX-497) offers a powerful way to interrogate guanine nucleotide dependence across antiviral and immune models. This article explains how recent PEDV research can improve assay design, controls, and interpretation beyond simple compound screening.
-
RNA Synthesis as a Lens on Viral Immune Evasion
2026-08-11
Mechanistic studies of SARS-CoV-2 nucleocapsid protein reveal how RNA–protein condensates can suppress GADD34-linked innate immunity. This article translates those insights into practical strategies for sequence-defined RNA synthesis, probe engineering, validation, and translational research.
-
HyperScribe T7 RNA Synthesis Kit Guide
2026-08-11
The HyperScribe T7 High Yield RNA Synthesis Kit is an in vitro transcription RNA kit for high-yield T7 RNA polymerase transcription. Its standard 20 μL reaction is specified to produce up to approximately 50 μg of RNA from 1 μg of control template, while supporting capped, labeled, and modified RNA research workflows.
-
AG-126: A Causal Map for ERK Assays
2026-08-10
AG-126 and Tyrphostin AG-126 provide a focused pharmacological probe for ERK1/2 signaling. This article explains how to use the compound to separate pathway activity, cell-type mechanisms, and functional outcomes in inflammation and neurodevelopmental research.
-
Caspase-3 in the Autophagy–Apoptosis Axis
2026-08-09
A mechanistic and translational framework for using DEVD-dependent caspase activity measurement to distinguish pathway engagement from irreversible cell death, with renal cell carcinoma as the anchor model.
-
Nadolol (SQ-11725): From Signaling to Translation
2026-08-08
Nadolol (SQ-11725) is more than a beta-receptor tool: its non-selective pharmacology and transporter-linked disposition create an opportunity to connect beta-adrenergic signaling with exposure, tissue distribution, and disease-state biology. This article outlines a translational strategy for using Nadolol in cardiovascular research while responsibly interpreting lessons from pharmacokinetic studies in metabolic disease.